Attached files

file filename
EX-31.1 - EXHIBIT 31.1 - IRIS BIOTECHNOLOGIES INCex311.htm
EX-32.1 - EXHIBIT 32.1 - IRIS BIOTECHNOLOGIES INCex321.htm
EXCEL - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCFinancial_Report.xls
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 10-Q
 
(Mark One)
 
x
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended September 30, 2011
 
OR
 
o
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from               to            
 
COMMISSION FILE NUMBER 333-142076
 
IRIS BIOTECHNOLOGIES INC.
(Exact Name of small business issuer as specified in its charter)
 
California
 
77-0506396
(State or other jurisdiction of
 
(I.R.S. Employer
incorporation or organization)
 
Identification No.)
 
5201 Great America Parkway, Suite 320, Santa Clara, California 95054
(Address of principal executive offices) (Zip Code)
 
Issuer’s telephone Number: (408) 867-2885
 
Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x   No o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o   No x
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
 
Large accelerated filer o
 
Accelerated filer  o
     
Non-accelerated filer o
 
Smaller reporting company  x
(Do not check if a smaller
reporting company)
   
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o   No x
 
As of November 11, 2011 the issuer had 12,354,251 outstanding shares of Common Stock.
  
 
1

 
 
 
TABLE OF CONTENTS
 
   
Page
 
PART I
 
     
Item 1.
Financial Statements
3
     
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operation
18
     
Item 4
Controls and Procedures
23
     
 
PART II
 
     
Item 1.
Legal Proceedings
24
     
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
24
     
Item 6.
Exhibits
24
     
  Signatures 25
 
 
2

 
 
PART I
 
ITEM 1. FINANCIAL STATEMENTS.
 
INDEX TO FINANCIAL STATEMENTS
 
 
Page
Condensed Balance Sheets as of September 30, 2011 (unaudited) and December 31, 2010
4
   
Unaudited Condensed Statements of Income (Losses) for the three and nine months ended September 30, 2011 and 2010 and the period February 16, 1999 (date of inception) to September 30, 2011
5
   
Unaudited Condensed Statement of Stockholders’ Deficit for the nine months ended September 30, 2011
6
   
Unaudited Condensed Statements of Cash Flows for the nine months ended September 30, 2011 and 2010 and the period February 16, 1999 (date of inception) to September 30, 2011
7
   
Notes to the Unaudited Condensed Financial Statements
8

 
 
3

 

IRIS BIOTECHNOLOGIES, INC
 
(a development stage company)
 
CONDENSED BALANCE SHEETS
 
             
   
September 30,
   
December 31,
 
   
2011
   
2010
 
   
(unaudited)
       
ASSETS
           
Current assets:
           
Cash
  $ 78,779     $ 3,222  
  Total current assets
    78,779       3,222  
                 
Property, plant and equipment, net of accumulated depreciation of $211,648 and $199,861 as of September 30, 2011 and December 31, 2010, respectively
    24,035       32,158  
                 
Total assets
  $ 102,814     $ 35,380  
                 
LIABILITIES AND STOCKHOLDERS' DEFICIT
               
Current liabilities:
               
Accounts payable
  $ 58,597     $ 102,483  
Accrued liabilities
    -       432,000  
Notes payable, related party
    -       53,400  
  Total current liabilities
    58,597       587,883  
                 
Long term debt:
               
Convertible notes payable
    90,000       25,000  
Convertible note payable, related party net of debt discount of $10,479 and $13,247 as of September 30, 2011 and December 31, 2010, respectively
    66,725       89,332  
  Total liabilities
    215,322       702,215  
                 
Commitments and contingencies
               
                 
STOCKHOLDERS' DEFICIT
               
Preferred stock, no par; 5,000,000 shares authorized; no shares issued and outstanding as of September 30, 2011 and December 31, 2010
    -       -  
Common stock, no par; 20,000,000 shares authorized; 12,212,751 and 11,641,913 shares issued and outstanding as of September 30, 2011 and December 31, 2010,  respectively
    6,102,066       5,527,508  
Additional paid in capital
    2,240,147       2,101,945  
Common stock subscription
    78,000       -  
Common stock subscription receivable
    (128,375 )     (163,750 )
Deficit accumulated during development stage
    (8,404,346 )     (8,132,538 )
  Total stockholders' deficit
    (112,508 )     (666,835 )
                 
Total liabilities and stockholders' deficit
  $ 102,814     $ 35,380  
                 
The accompanying notes are an integral part of these unaudited condensed financial statements
 
 
 
4

 
 
IRIS BIOTECHNOLOGIES, INC
 
(a development stage company)
 
CONDENSED STATEMENTS OF INCOME (LOSSES)
 
(unaudited)
 
       
   
Three months ended September 30,
   
Nine months ended September 30,
   
For the period from
 
   
2011
   
2010
   
2011
   
2010
   
February 16, 1999 (date of inception) through September 30, 2011
 
Operating expenses:
                             
Selling, general and administrative
  $ 106,863     $ 204,220     $ 336,200     $ 483,358     $ 4,611,983  
Research and development (Note 1)
    46,144       2,247       125,143       51,343       1,979,364  
Impairment of intellectual property
    -       -       -       -       1,838,250  
Depreciation
    3,970       3,909       11,787       12,822       211,648  
  Total operating expenses
    156,977       210,376       473,130       547,523       8,641,245  
                                         
 Net loss from operations
    (156,977 )     (210,376 )     (473,130 )     (547,523 )     (8,641,245 )
                                         
Other income (expense)
                                       
Grant income
    -       -       209,671       -       244,480  
Interest expense
    (2,844 )     (3,706 )     (8,349 )     (6,731 )     (7,581 )
                                         
Net loss before provision for income taxes
    (159,821 )     (214,082 )     (271,808 )     (554,254 )     (8,404,346 )
                                         
Income taxes
    -       -       -       -       -  
                                         
Net loss
  $ (159,821 )   $ (214,082 )   $ (271,808 )   $ (554,254 )   $ (8,404,346 )
                                         
Loss per common share-basic and fully diluted
  $ (0.01 )   $ (0.02 )   $ (0.02 )   $ (0.05 )   $ (0.85 )
                                         
Weighted average number of common shares outstanding-basic and fully diluted
    12,161,608       11,554,404       12,101,863       11,318,128       9,886,683  
                                         
The accompanying notes are an integral part of these unaudited condensed financial statements
 

 
5

 
IRIS BIOTECHNOLOGIES, INC
 
(a development stage company)
 
CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT
 
FROM JANUARY 1, 2011 THROUGH SEPTEMBER 30, 2011
 
(unaudited)
 
                                                       
                                 
Common
         
Deficit accumulated
       
   
Preferred shares
   
Common shares
   
Additional
   
Stock
   
Subscription
   
during
       
   
Stock
   
Amount
   
Stock
   
Amount
   
Paid in Capital
   
Subscription
   
Receivable
   
Development stage
   
Total
 
Balance, January 1, 2011
    -     $ -       11,641,913     $ 5,527,508     $ 2,101,945     $ -     $ (163,750 )   $ (8,132,538 )   $ (666,835 )
Common stock issued in January 2011 in exchange for accounts payable and accruals at $1.00 per share
    -       -       66,000       66,000       -       -       -       -       66,000  
Common stock issued in January 2011 in exchange for accounts payable and accruals at $1.11 per share
    -       -       353,838       392,760       -       -       -       -       392,760  
Common stock issued in March 2011 at $1.00 per share in exchange for services rendered
    -       -       8,000       8,000       -       -       -       -       8,000  
Common stock subscription offset by note payable
    -       -       -       -       -       -       34,375       -       34,375  
Common stock issued in April 2011 at $0.95 per share in exchange for services rendered
    -       -       8,000       7,600       -       -       -       -       7,600  
Common stock issued in April 2011 at $1.06 per shares as board compensation
    -       -       37,750       40,015       -       -       -       -       40,015  
Common stock issued in May 2011 at $0.80 per share in exchange for services rendered
    -       -       8,000       6,400       -       -       -       -       6,400  
Common stock issued in June 2011 at $0.80 per share in exchange for services rendered
    -       -       8,000       6,400       -       -       -       -       6,400  
Common stock issued in August 2011 at $0.57 per share in exchange for services rendered
    -       -       8,000       4,560       -       -       -       -       4,560  
Common stock issued in August 2011 at $0.85 per share as board compensation
    -       -       37,250       31,663       -       -       -       -       31,663  
Sale of common stock in August 2011 at $0.25 per share
    -       -       20,000       5,000       -       -       -       -       5,000  
Common stock issued in September 2011 at $0.27 per share in exchange for services rendered
    -       -       8,000       2,160       -       -       -       -       2,160  
Common stock issued in September 2011 at $0.50 per share in exchange for services rendered
    -       -       8,000       4,000       -       -       -       -       4,000  
Proceeds received for common stock subscription of 78,000 of common stock
    -       -       -       -       -       78,000       -       -       78,000  
Proceeds received from common stock subscription
    -       -       -       -       -       -       1,000       -       1,000  
Fair value of vested options issued for services
    -       -       -       -       138,202       -       -       -       138,202  
Net loss
    -       -       -       -       -       -       -       (271,808 )     (271,808 )
Balance, September 30, 2011
    -     $ -       12,212,751     $ 6,102,066     $ 2,240,147     $ 78,000     $ (128,375 )   $ (8,404,346 )   $ (112,508 )
                                                                         
The accompanying notes are an integral part of these unaudited condensed financial statements
 
 
6

 
 
IRIS BIOTECHNOLOGIES, INC
 
(a development stage company)
 
CONDENSED STATEMENTS OF CASH FLOWS
 
 (unaudited)  
                   
   
Nine months ended September 30,
   
For the period from
 
   
2011
   
2010
   
February 16, 1999 (date of inception) through September 30, 2011
 
CASH FLOWS FROM OPERATING ACTIVITIES:
                 
Net loss
  $ (271,808 )   $ (554,253 )   $ (8,404,346 )
Adjustments to reconcile net loss to cash (used in) operating activities:
                       
Depreciation
    11,787       12,821       211,321  
Amortization of deferred compensation
    -       -       46,926  
Amortization of beneficial conversion feature relating to convertible debt
    2,768       1,164       4,697  
Common stock issued in exchange for services rendered
    110,798       211,730       654,337  
Impairment of intellectual property
    -       -       1,800,000  
Options and warrants issued in exchange for services rendered
    138,202       103,891       2,178,045  
Increase (decrease) in:
                       
Accounts payable and accrued liabilities
    (17,126 )     57,920       537,255  
Net cash used in operating activities:
    (25,379 )     (166,727 )     (2,971,765 )
                         
CASH FLOWS FROM INVESTING ACTIVITIES:
                       
Acquisition of property, plant and equipment
    (3,664 )     -       (225,255 )
Net cash used in investing activities:
    (3,664 )     -       (225,255 )
                         
CASH FLOWS FROM FINANCING ACTIVITIES:
                       
Proceeds from issuance of note payable
    65,000       81,454       146,454  
Proceeds from sale of common stock
    84,000       118,252       3,024,845  
Exercise of common stock options
    -       -       42,500  
Net (payments) proceeds, related party
    (44,400 )     (33,300 )     62,000  
Net cash  provided by financing activities
    104,600       166,406       3,275,799  
                         
Increase (decrease) in cash and cash equivalents
    75,557       (321 )     78,779  
Cash and cash equivalents beginning of period
    3,222       442       -  
Cash and cash equivalents end of period
  $ 78,779     $ 121     $ 78,779  
                         
Supplemental disclosures of cash flow information:
                       
Cash paid during the period for interest
  $ -     $ -     $ 277  
Cash paid during the period for taxes
  $ -     $ -     $ -  
Non cash Investing and Financing Activities                        
Convertible debt adjusted with subscription receivable
  $ 34,375     $ -     $ 41,250  
Beneficial conversion feature of convertible notes payable
  $ -     $ -     $ 15,176  
Common stock issued in exchange for intellectual property
  $ -     $ -     $ 1,800,000  
                         
The accompanying notes are an integral part of these unaudited condensed financial statements
 
 
 
7

 

IRIS BIOTECHNOLOGIES INC.
(A development stage company)
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2011
(Unaudited)


NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
A summary of the significant accounting policies applied in the preparation of the accompanying unaudited condensed financial statements follows.
 
General
 
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.
 
In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Accordingly, the results from operations for the nine month period ended September 30, 2011, are not necessarily indicative of the results that may be expected for the year ended December 31, 2011. The unaudited condensed financial statements should be read in conjunction with the December 31, 2010 financial statements and footnotes thereto included in the Company’s Form 10-K filed on April 6, 2011.
 
Business and Basis of Presentation
 
Iris BioTechnologies Inc. (the “Company”) was incorporated on February 16, 1999 under the laws of the State of California. The Company is in the development stage as defined under Accounting Standards Codification subtopic 915-10 Development Stage Entities and its efforts are principally devoted to developing solutions for the detection and monitoring of monogenic and complex genomic diseases. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. For the period from inception through September 30, 2011, the Company has accumulated losses of $8,404,346.
 
Cash
 
For purposes of the Statements of Cash Flows, the Company considers all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents.
 
Property and Equipment
 
Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years.
 
Use of Estimates
 
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates
 
 
8

 

IRIS BIOTECHNOLOGIES INC.
(A development stage company)
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2011
(Unaudited)

Long-Lived Assets
 
The Company follows Accounting Standards Codification subtopic 360-10, Property, plant and equipment (“ASC 360-10”). The Statement requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.
 
Income Taxes
 
The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and relate primarily to stock based compensation basis differences.  As of September 30, 2011, the Company has provided a 100% valuation against the deferred tax benefits.
 
Net Loss Per Common Share
 
The Company computes earnings per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. For the three and nine months ended September 30, 2011 and 2010 common stock equivalents derived from shares issuable on conversion of convertible notes and the exercise of options and warrants are not considered in the calculation of the weighted average number of common shares outstanding because they would be anti-dilutive, thereby decreasing the net loss per share.
 
Concentrations of Credit Risk
 
Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and related party receivables. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. The Company periodically reviews its trade receivables in determining its allowance for doubtful accounts. The Company does not have accounts receivable at September 30, 2011 and December 31, 2010.
 
 
9

 

IRIS BIOTECHNOLOGIES INC.
(A development stage company)
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2011
(Unaudited)
 

Research and Development
 
The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenditures of $46,144 and $2,247 for the three months ended September 30, 2011 and 2010, respectively; $125,143 and $51,343 for the nine months ended September 30, 2011 and 2010, respectively and $1,979,364 from the period from February 16, 1999 (date of inception) to September 30, 2011.
 
During the nine months ended September 30, 2011, the Company received $209,671 grant income under the a federal program entitled the Qualifying Therapeutic Discovery Project. The grant was only available to taxpayers with no more than 250 employees and covers up to 50 percent of qualified investment made in 2009 and 2010 within the overall cap.
 
Liquidity and Dependency of Key Management
 
To date the Company has generated no revenues, has incurred expenses, and has sustained losses. As shown in the accompanying unaudited condensed financial statements, the Company incurred a loss of $271,808 during the nine months ended September 30, 2011 and $554,254 during the nine months ended September 30, 2010. For the period from February 16, 1999 (date of inception) through September 30, 2011, the Company has accumulated losses of $8,404,346. Consequently, its operations are subject to all risks inherent in the establishment of a new business enterprise.
 
The future success or failure of the Company is dependent primarily upon the continued efforts and financial support of Simon Chin, the Company’s Chief Executive Officer, Chief Financial Officer and the majority shareholder (see Note 3). As in the past, Mr. Chin has committed to provide all necessary funding needed to the meet the Company’s financial obligations through 2011.
  
Fair Value of Financial Instruments
 
Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. There were no items required to be measured at fair value on a recurring basis in the financial statement as of September 30, 2011.
 
The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows.
 
 
10

 

IRIS BIOTECHNOLOGIES INC.
(A development stage company)
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2011
(Unaudited)

Stock Based Compensation
 
The Company follows the fair value recognition provisions of Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) using the modified-prospective transition method. Under this transition method, stock-based compensation expense was recognized in the financial statements for granted, modified, or settled stock options. Compensation expense recognized included the estimated expense for stock options granted on and subsequent to January 1, 2006, based on the grant date fair value estimated in accordance with the provisions of ASC 718-10, and the estimated expense for the portion vesting in the period for options granted prior to, but not vested as of January 1, 2006, based on the grant date fair value estimated in accordance with the original provisions of ASC 718-10. Results for prior periods have not been restated, as provided for under the modified-prospective method.
 
ASC 718-10 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. In the Company’s pro forma information required under ASC 718- 10 for the periods prior to fiscal 2006, the Company accounted for forfeitures as they occurred.
 
Upon adoption of ASC 718-10, the Company is using the Black-Scholes option-pricing model as its method of valuation for share-based awards granted beginning in fiscal 2006, which was also previously used for the Company’s pro forma information required under ASC 718-10 The Company’s determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by the Company’s stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to the Company’s expected stock price volatility over the term of the awards, and certain other market variables such as the risk free interest rate.
 
For the nine months ended September 30, 2011 and 2010, the Company granted 285,000 and Nil employee stock options, respectively. The fair value of issued vesting options is $115,597 and $70,736 for the nine months ended September 30, 2011 and 2010, respectively.
 
Recent Accounting Pronouncements
 
There were various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.
 
NOTE 2 - PROPERTY, PLANT, AND EQUIPMENT
 
Property, plant and equipment at September 30, 2011 and December 31, 2010 are as follows:

   
September 30, 2011
(unaudited)
   
December 31, 2010
 
Computer equipment
 
$
64,866
   
$
61,201
 
Office equipment
   
1,728
     
1,728
 
Furniture and fixtures
   
3,586
     
3,586
 
Manufacturing equipment
   
165,503
     
165,503
 
     
235,683
     
232,018
 
Less: accumulated depreciation
   
(211,648
)
   
(199,860
)
   
$
24,035
   
$
32,158
 
 
 
11

 

IRIS BIOTECHNOLOGIES INC.
(A development stage company)
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2011
(Unaudited)

During the nine months ended September 30, 2011 and 2010, depreciation expense charged to operations was $11,787 and $12,822, respectively, and $3,970 and $3,909 for the three months ended September 30, 2011 and 2010, respectively.
 
NOTE 3 — RELATED PARTY CONVERTIBLE NOTES PAYABLE
 
On September 24, 2009, the Company issued a note totaling $38,000 to a shareholder/director, unsecured and bearing an interest rate of 7.5% per annum, due five years from date of issuance. The notes are convertible into the Company’s common stock at a conversion rate of $2.25 per share. On November 3, 2010 and January 2, 2011, $6,875 and $31,125 of the outstanding note was offset by a common stock subscription receivable due to the Company. During the nine months ended September 30, 2011 and 2010, the Company has charged $0 and $2,132, respectively and $-0- and $718 for the three months ended September 30, 2011 and 2010, respectively to interest expense.
 
One of our board members owns 40% of an entity that entered into a 5-year, 7.5% interest, convertible note agreement with the Company for the amount of $71,454 in May 2010. The note is convertible at any time prior to maturity, at the holder’s option, into shares of our common stock at $1.13 per share. On January 2, 2011, $3,250 of the outstanding note payable was offset by a common stock subscription receivable due the Company. During the nine months ended September 30, 2011, the Company has charged $6,594 to interest expense inclusive of debt discount amortization.
 
In accordance with ASC 470-20, the Company recognized an embedded beneficial conversion feature present in the note. The Company allocated a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. The Company recognized and measured an aggregate of $15,176 of the proceeds, which is equal to the intrinsic value of the embedded beneficial conversion feature, to additional paid-in capital and a discount against the note. The debt discount attributed to the beneficial conversion feature is charged to current period operations as interest expense using the effective interest method over the term of the note.
 
During the three and nine months ended September 30, 2011, the Company recorded an amortization of the discount of $730 and $2,768, respectively as a charge against current period interest expense.

In addition, on August 24, 2011, our board member described above entered into a 5-year, 7.5% interest,  convertible note agreement with the Company for the amount of $9,000. The note is convertible at any time prior to maturity, at the holder’s option, into shares of our common stock at $1.00 per share.  Based upon the value of the stock an embedded beneficial conversion feature was not present in the note. During the nine months ended September 30, 2011, the Company has charged $85 to interest expenses.

Convertible related party notes at September 30, 2011 and December 31, 2010 are as follows:

   
September 30, 2011
(unaudited)
   
December 31,
 2010
 
       Convertible notes payable, related party
 
$
9,000
   
$
31,125
 
       Convertible note payable, related party net of debt discount of $10,479  and $13,247, respectively
   
57,725
     
58,207
 
        Total
   
66,725
     
89,332
 
        Less: current portion
   
     
 
        Long term portion
 
$
66,725
   
$
89,332
 
 
 
12

 

IRIS BIOTECHNOLOGIES INC.
(A development stage company)
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2011
(Unaudited)

 
Aggregate maturities of long-term debt as of September 30, 2011 are as follows:

Year ended
 
Amount
 
        December 31, 2011
 
$
 
        December 31, 2012
 
 
        December 31, 2013
 
 
        December 31, 2014
 
 
        December 31, 2015 and above
 
77,204
 
        Total
 
77,204
 
        Less: Debt Discount
 
10,479
 
        Total
 
$
66,725
 
 
The Company’s President and shareholders have advanced funds on a non-interest-bearing basis to the Company for working capital purposes since the Company’s inception in February 1999.  No formal repayment terms or arrangements exist. The net amount outstanding at September 30, 2011 and December 31, 2010 was $Nil and $53,400, respectively.
 
NOTE 4 - LONG TERM CONVERTIBLE NOTES PAYABLE
 
Long-term debt at September 30, 2011 and December 31, 2010 are as follows:

   
September 30, 2011 (unaudited)
   
December 31,
 2010
 
        Note payables
 
$
90,000
   
$
25,000
 
        Total
   
90,000
     
25,000
 
        Less: current portion
   
     
 
        Long term portion
 
$
90,000
   
$
25,000
 
 
On October 9, 2009, the Company issued a $5,000 note to an unrelated party, unsecured and bearing an interest rate of 7.5% per annum, due five years from date of issuance. The note is convertible into the Company’s common stock at a conversion rate of $2.25 per share.
 
On December 23, 2009, the Company issued a $10,000 note to an unrelated party, unsecured and bearing an interest rate of 7.5% per annum, due five years from date of issuance. The note is convertible into the Company’s common stock at a conversion rate of $2.25 per share.
 
On January 10, 2010, the Company issued a $10,000 note to an unrelated party, unsecured and bearing an interest rate of 7.5% per annum, due five years from date of issuance. The note is convertible into the Company’s common stock at a conversion rate of $2.25 per share.
 
On September 2, 2011, the Company issued a $25,000 note to an unrelated party, unsecured and bearing an interest rate of 7.5% per annum, due five years from date of issuance. The note is convertible into the Company’s common stock at a conversion rate of $1.00 per share.
 
On September 15, 2011, the Company issued a $40,000 note to an unrelated party, unsecured and bearing an interest rate of 7.5% per annum, due five years from date of issuance. The note is convertible into the Company’s common stock at a conversion rate of $1.00 per share.
 
 
13

 

IRIS BIOTECHNOLOGIES INC.
(A development stage company)
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2011
(Unaudited)


NOTE 5 - STOCKHOLDER EQUITY
 
Preferred stock
 
The Company is authorized to issue 5,000,000 shares of no par preferred stock. From date of inception through September 30, 2011, the Company has not issued any preferred shares.
 
Common stock
 
During the nine months ended September 30, 2011, the Company issued an aggregate of 550,838 shares of common stock for services in the amount of $569,558 out of which 419,838 shares of common stock were issued for a value of $458,760 related to prior accruals no gain or loss was recognized.
  
Warrants
 
The following table summarizes the changes in warrants outstanding and related prices for the shares of the Company’s common stock issued to shareholders at September 30, 2011:
 
Exercise
Price
 
Number
Outstanding
 
Warrants Outstanding
Weighted Average
Remaining Contractual
Life (years)
 
Weighted
Average
Exercise price
 
Number
Exercisable
 
Warrants Exercisable
Weighted
Average
Exercise Price
 
$
 0.13
 
40,000
 
2.72
 
$
0.13
 
40,000
 
$
0.13
 
$
 2.00
 
13,900
 
0.32
 
 
2.00
 
13,900
 
 
2.00
 
$
 2.25
 
23,629
 
1.39
 
 
2.25
 
23,629
 
 
2.25
 
   
77,529
         
77,529
     
 
Transactions involving the Company’s warrant issuance are summarized as follows:
 
   
Number of
Shares
   
Weighted
Average
Price Per Share
 
        Outstanding at December 31, 2009
   
95,029
   
$
1.29
 
        Issued
   
     
 
        Exercised
   
     
 
        Canceled or expired
   
     
 
        Outstanding at December 31, 2010
   
95,029
   
$
1.29
 
        Issued
   
     
 
        Exercised
   
     
 
        Expired
   
(17,500
)
   
(2.00
)
        Outstanding at September 30, 2011
   
77,529
   
$
1.11
 
 
Options  
 
Employee Options
 
The following table summarizes the changes in options outstanding and the related prices for the shares of the Company’s common stock issued to employees under a stock option plan at September 30, 2011:
 
 
14

 

IRIS BIOTECHNOLOGIES INC.
(A development stage company)
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2011
(Unaudited)

     
Options Outstanding
   
Options Exercisable
 
Exercise
Prices (S)
   
Number
Outstanding
   
Weighted Average
Remaining
Contractual Life
(Years)
   
Weighted
Average
Exercise
Price (S)
   
Number
Exercisable
   
Weighted
Average
Exercise
Price
 
$ 0.13       80,000       7.72     $ 0.13       80,000     $ 0.13  
  0.15       400,000       2.72       0.15       400,000       0.15  
  0.80       85,000       9.46       0.80       10,625       0.80  
  1.00       761,875       4.38       1.00       761,875       1.00  
  1.11       200,000       9.26       1.11       33,333       1.11  
  2.25       167,696       6.65       2.25       139,747       2.25  
          1,694,571               0.88       1,425,580       0.84  
 
Transactions involving employee stock options issued are summarized as follows:
 
   
Number of Shares
   
Weighted Average
Price Per Share
 
        Outstanding at December 31, 2009:
   
1,689,446
   
$
0.85
 
        Granted
   
     
 
        Exercised
   
(86,875
)
   
(0.71
)
        Canceled or expired
   
(121,000
)
   
(0.92
)
        Outstanding at December 31, 2010
   
1,481,571
   
$
0.86
 
        Granted
   
285,000
     
1.02
 
        Exercised
   
     
 
        Expired
   
(72,000
)
   
(0.86
)
        Outstanding at September 30, 2011:
   
1,694,571
   
$
0.88
 
 
On January 2, 2011, the Company granted 200,000 employee stock options with an exercise price of $1.11 vesting over four years and expiring ten years from issuance. The fair value (as determined as described below) of $219,376 is charged ratably over the vesting term of the options.
 
The fair value of these stock options granted and the significant assumptions used to determine those fair values, using a Black-Scholes option-pricing model are as follows:
 
Significant assumptions:
     
        Risk-free interest rate at grant date
    3.30 %
        Expected stock price volatility
    155.50 %
        Expected dividend payout
     
        Expected option life-years (a)
    10  
__________________________
(a)The expected option life is based on contractual expiration dates
 
On March 16, 2011, the Company granted 85,000 employee stock options with an exercise price of $0.80 vesting over four years and expiring ten years from issuance. The fair value (as determined as described below) of $66,389 is charged ratably over the vesting term of the options.
 
The fair value of these stock options granted and the significant assumptions used to determine those fair values, using a Black-Scholes option-pricing model are as follows:
 
 
15

 

IRIS BIOTECHNOLOGIES INC.
(A development stage company)
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2011
(Unaudited)

 Significant assumptions:
     
        Risk-free interest rate at grant date
    3.22 %
        Expected stock price volatility
    139.10 %
        Expected dividend payout
     
        Expected option life-years (a)
    10  
___________________________
 
(a)The expected option life is based on contractual expiration dates
 
The fair value of the vested portion previously granted employee options of $41,439 and $23,578 was charged during the three months ended September 30, 2011 and 2010, respectively and $115,597 and $70,736 during the nine months ended September 30, 2011 and 2010, respectively.
 
Non-employee options
 
The following table summarizes the changes in options outstanding and the related prices for the shares of the Company’s common stock issued to non-employees under a stock option plan at September 30, 2011:
 
     
Options Outstanding
   
Options Exercisable
 
Exercise
Prices
   
Number
Outstanding
   
Weighted Average
Remaining
Contractual Life
(Years)
   
Weighted
Average
Exercise
Price
   
Number
Exercisable
   
Weighted
Average
Exercise
Price
 
$ 0.50       40,000       0.61     $ 0.50       40,000     $ 0.50  
  1.00       110,000       4.46       1.00       110,000       1.00  
  1.40       105,000       7.49       1.40       81,667       1.40  
          255,000               1.09       231,667       1.05  
 
Transactions involving non-employee stock options issued are summarized as follows:

   
Number of Shares
   
Weighted Average
Price Per Share
 
       Outstanding at December 31, 2009:
   
375,000
   
$
0.90
 
       Granted
   
     
 
       Exercised
   
     
 
       Canceled or expired
   
     
 
       Outstanding at December 31, 2010
   
375,000
   
$
0.90
 
       Granted
   
     
 
       Exercised
   
     
 
       Expired
   
(120,000
)
   
(0.50
)
       Outstanding at September 30, 2011:
   
255,000
   
$
1.09
 

The fair value of the vested portion of previously granted non-employee options of $6,848 and $9,617 was charged during the three months ended September 30, 2011 and 2010, respectively and $22,605 and $33,154 during the nine months ended September 30, 2011 and 2010, respectively
 
 
16

 

IRIS BIOTECHNOLOGIES INC.
(A development stage company)
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2011
(Unaudited)

 
NOTE 7 - SUBSEQUENT EVENTS
 
In the month of October 2011, the Company issued an aggregate of 8,000 shares of its common stock for services rendered in October 2011, 37,500 shares were issued as board of director fees for the quarter ended September 30, 2011 and 88,000 shares for the sale of common stock at $1.00 per share, of which $78,000 was received in September 2011 shown as common stock subscription.

In the month of November 2011, the Company issued an aggregate of 8,000 shares of its common stock for services rendered in November.

 
 










 
17

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
 
Forward-Looking Statements
 
The information in this report contains forward-looking statements. All statements other than statements of historical fact made in this report are forward looking. In particular, the statements herein regarding industry prospects and future results of operations or financial position are forward-looking statements. These forward-looking statements can be identified by the use of words such as “believes,” “estimates,” “could,” “possibly,” “probably,” anticipates,” “projects,” “expects,” “may,” “will,” or “should” or other variations or similar words. No assurances can be given that the future results anticipated by the forward-looking statements will be achieved. Forward-looking statements reflect management’s current expectations and are inherently uncertain. Our actual results may differ significantly from management’s expectations.
 
The following discussion and analysis should be read in conjunction with our financial statements, included herewith. This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future. Such discussion represents only the best present assessment of our management.
 
Overview
 
Since inception on February 16, 1999 through September 30, 2011, we have sustained cumulative net losses of $8,404,346. Our losses have resulted primarily from research and development expenses, patent costs and legal and accounting expenses. From inception through September 30, 2011, we have not generated any revenue from operations. We expect to incur additional losses to perform further research and development activities. We have sufficient cash to operate for one year at the current burn rate with our CEO’s agreement to fund our operations. In order to accelerate our product introduction and to grow dynamically, we will need to raise additional funds. We do not currently have any commercial products. With additional funding, we expect to launch our nano-biochip products in less than a year.
 
During the past two years, we have spent less than $10,000 for public relations. Due to the severe recession we felt that is was prudent to spend investor dollars on designing and building an advanced Nano-Biochip making system, streamlining the automated patient sample processing protocols and product tracking system, and interacting with physicians and patients to demonstrate the usefulness of our BioWindows™ medical informatics system. We have an extensive pipeline of disease chips including a BreastCancerChip™, ColonCancerChip™, NeuroChip™, CardioChip™, ComprehensiveCancerChip™, and MetabolicChip™.
 
We have been in discussions with various entities in regard to launching our products in the US and abroad. We have also had discussions with equipment financing sources with respect to building or buying additional equipment, which would allow us to expand our manufacturing capacity. Under the US Qualifying Therapeutic Discovery Project (QTDP) Program, the maximum amount of a grant application was $5 million, but the maximum amount that the government actually gave for any grant was $245,000. We were awarded $245,000 in recognition of our patented Nano-Biochip™ and BioWindows™ Medical Informatics System for optimizing personalized and targeted medical treatment.
 
The selection criteria includes a company’s ability to diagnose diseases or conditions; to determine molecular factors related to diseases or conditions by developing molecular diagnostic guided therapeutic decisions; or to develop a product, process, or technology to further the delivery or administration of therapeutics. The award was given to projects that show reasonable potential to result in new therapies to treat areas of unmet medical needs or to prevent, detect or treat chronic or acute diseases and conditions; to reduce long-term health care costs in the U.S.; or to significantly advance the goal of curing cancer within the next 30 years.
 
 
18

 
 
 There are some risks with respect to clinical testing, regulatory approval and review cycles and uncertainty of the costs. Net positive cash inflows from any products developed may take several years to achieve. Management plans to continue financing operations with a combination of equity issuances and debt arrangements. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate our research or development programs, or cease operations.
 
History
 
We were incorporated in the State of California on February 16, 1999 and planned to sell theranostic (choosing therapy based upon personalized diagnostic results) products and services in the medical field. In an effort to develop that business, we set up operations in two locations in California - Headquarters in Santa Clara and Laboratory in San Leandro.
 
Beginning on March 11, 1999, Simon Chin, MBA, our founder, President and CEO, Secretary and principal shareholder, entered into Common Stock Purchase Agreements with various companies, investment groups and private individuals. On March 1, 2003, Daniel Farnum, M.D., an owner of Humboldt Orthopedics and a key shareholder, and Grace Osborne, MBA, President of GCO Recruiting, joined Mr. Chin on our board of directors. On April 9, 2003, the board approved a 2 for 1 stock split, changed the authorized shares of common stock from 10 million to 20 million, and the authorized preferred stock remained at 5 million shares.
 
Plan of Operation
 
We are a life science company focused on the development and commercialization of Nano-BiochipsTM and an artificial intelligence system to assist in establishing the foundation for personalized medicine, which will initially be utilized in the treatment of breast cancer. The Nano-BiochipsTM have the ability to quickly and very accurately analyze the activity of multiple genes involved in a specific disease. Iris’s manufacturing system has the capability to produce a variety of chips with a choice of mRNA, microRNA, protein, or other biomarker probes for the diagnosis and prognosis of many diseases. Although we may market our products as CLIA laboratory tests, we are designing them to be approved by the FDA, which can then be used in any certified laboratory. Starting at the point of a breast biopsy diagnosis of cancer, the Nano-Biochip and informatics program are designed to enable a treating physician to quickly prescribe a personalized treatment regimen that will have the greatest probability of success for each patient’s particular type of cancer. Our product platform is expected to lead to more effective diagnosis and treatment not only for patients with breast cancer, but also for those with neurological disorders, heart disease, diabetes and other gene-related metabolic problems.
 
Product Research and Development
 
We anticipate spending, in order to accelerate our growth, which is contingent upon raising additional funds, more than $2 million for product research and development activities related to our anticipated product launch during the next twelve months.
 
Acquisition of Plant and Equipment and Other Assets
 
We do not anticipate the sale of any material property, plant or equipment during the next 12 months. We do not anticipate the acquisition of any material property, plant or equipment during the next 12 months, unless we raise additional funds to accelerate our growth to fulfill the unmet needs of a large, growing market.
 
 
19

 
 
 Number of Employees
 
From our inception through the period ended September 30, 2011, we have relied on the services of full time and part-time employees as well as outside consultants. As of November 11, 2011, we have five full time and seven part-time employees and consultants. In order for us to attract and retain quality personnel, we anticipate we will have to offer competitive salaries to future employees. We anticipate that it may become desirable to add additional full and or part time employees to discharge certain critical functions during the next 12 months. This projected increase in personnel is dependent upon our ability to generate revenues and obtain sources of financing. There is no guarantee that we will be successful in raising the funds required or generating revenues sufficient to fund the projected increase in the number of employees. As we continue to expand, we will incur additional cost for personnel.
 
Results of Operations
 
We are in the development stage and to date have not generated revenues. The risks specifically discussed are not the only factors that could affect future performance and results. In addition to the discussion in this prospectus concerning us, our business and our operations contain forward-looking statements. Such forward-looking statements are necessarily speculative and there are certain risks and uncertainties that could cause actual events or results to differ materially from those referred to in such forward-looking statements. We do not have a policy of updating or revising forward-looking statements and thus it should not be assumed that silence by our Management over time means that actual events or results are occurring as estimated in the forward-looking statements herein.
 
As a development stage company, we have yet to earn revenues from operations. We may experience fluctuations in operating results in future periods due to a variety of factors, including our ability to obtain additional financing in a timely manner and on terms favorable to us, our ability to successfully develop our business model, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure and the implementation of marketing programs, key agreements, and strategic alliances, and general economic conditions specific to our industry.
 
As a result of limited capital resources and no revenues from operations since inception, we have relied on the issuance of equity securities to employees and non-employees (consultants) in exchange for services. Our management enters into equity compensation agreements with non-employees if it is in our best interest under terms and conditions consistent with the requirements of Accounting Standards Codification Subtopic 718-10 Compensation (ASC 718- 10). In order to conserve our limited operating capital resources, we anticipate continuing to compensate non-employees with equity for services during the next twelve months. This policy may have a material effect on our results of operations during the next twelve months.
 
Three Months Ended September 30, 2011 Compared to Three Months Ended September 30, 2010

Revenues
 
We have generated no operating revenues from operations from our inception.
 
Costs and Expenses
 
From our inception through September 30, 2011, we have incurred cumulative losses of $8,404,346. In addition, a significant part of the overall remaining costs are associated principally with equity-based compensation to employees and consultants, research and development costs and professional services rendered.
 
 
20

 
  
Selling, general and administrative (“SG&A”) expenses decreased by $97,357 from $204,220 for the three months ended September 30, 2010 to $106,863 for the three months ended September 30, 2011. SG&A expenses consisted of accounting, legal, consulting, public relations, startup and organizational expenses. SG&A expenses also included non-cash charges from the issuance of stock, warrants and stock options in the amounts of $90,669 for the three months ended September 30, 2011 and $119,996 for the three months ended September 30, 2010, a period to period decrease of $29,327. The remaining SG&A expenses, which required cash amounted to approximately $16,194 and $84,224 for the three months ended September 30, 2011 and 2010, respectively. We used stock in lieu of cash to conserve our cash resources.
 
Research and development costs increased from $2,247 for the three months ended September 30, 2010 to $46,144 for the three months ended September 30, 2011.
 
As a result of the above-mentioned expenses, net losses decreased from $214,082 for the three months ended September 30, 2010 to a net loss of $159,977 for the three months ended September 30, 2011.
 
Nine Months Ended September 30, 2011 Compared to Nine Months Ended September 30, 2010

Revenues
 
We have generated no operating revenues from operations from our inception.
 
Costs and Expenses
 
SG&A expenses decreased by $147,158 from $483,358 for the nine months ended September 30, 2010 to $336,200 for the nine months ended September 30, 2011. SG&A expenses included non-cash charges from the issuance of stock, warrants and stock options in the amounts of $249,000 for the nine months ended September 30, 2011 and $315,621 for the nine months ended September 30, 2010, a period to period decrease of $66,621. The remaining SG&A expenses, which required cash amounted to approximately $87,200 and $167,737 for the nine months ended September 30, 2011 and 2010, respectively. We used stock in lieu of cash to conserve our cash resources.
 
Research and development costs increased from $51,343 for the nine months ended September 30, 2010 to $125,143 for the nine months ended September 30, 2011.
 
During the nine months ended September 30, 2011, we received $209,671 grant income from the U. S. Government for research previously done as compared to Nil for 2010.
 
As a result of the above-mentioned expenses and the grant income, net losses decreased from $554,254 for the nine months ended September 30, 2010 to a net loss of $271,808 for the nine months ended September 30, 2011.
 
 Liquidity and Capital Resources
 
As of September 30, 2011, we had working capital of $20,182 as compared to a working capital deficit of $584,661 as of December 31, 2010. Our cash position was $78,779 as of September 30, 2011 compared to $3,222 as of December 31, 2010. From inception to September 30, 2011 we have incurred an operating cash flow deficit of $2,971,765, which has been principally financed through the private placement of our common stock, advances from related parties, issuance of notes payable and financial support of the Company's Chief Executive Officer (CEO). As of September 30, 2011, we have long-term debt of $156,725.
 
 
21

 
 
We expect to continue to incur additional losses and negative cash flows from operating activities for the next twelve months.
 
Our available working capital and capital requirements will depend upon numerous factors, including progress of our research and development programs, our progress in and the cost of pre-clinical and clinical testing, the timing and cost of obtaining regulatory approvals, the cost of filing and prosecuting patent claims and other intellectual property rights, completing technological and market developments, current and future licensing relationships, the status of our competitors, and our ability to establish collaborative arrangements with other organizations .
 
Our continued operations will depend on whether we are able to raise additional funds through various potential sources, such as equity and debt financing, collaborative and licensing agreements, strategic alliances, and our ability to realize the full potential of our technology in development. Such additional funds may not become available on acceptable terms, if at all, and there can be no assurance that any additional funding that we do obtain will be sufficient to meet our needs in the long term. Through November 11, 2011, virtually all of our financing has been through private placements of common stock and warrants. We intend to continue to fund operations from cash on-hand and through the similar sources of capital previously described for the foreseeable future. We can give no assurances that any additional capital that we are able to obtain will be sufficient to meet our needs. We believe that we will continue to incur net losses and negative cash flows from operating activities for the next two years. Based on the resources available to us, we have sufficient cash to operate for one year at the current burn rate with our CEO’s agreement to continue fund our operations. We may need additional financing thereafter.
 
Off-Balance Sheet Arrangements
 
We do not have any off-balance sheet arrangements.
 
Inflation
 
It is our opinion that inflation has not had a material effect on our operations.

Critical Accounting Policies
 
Our unaudited condensed financial statements are prepared in accordance with accounting principles generally accepted in the United States of America, which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
 
The following accounting policies are critical in fully understanding and evaluating our reported financial results:
 
 Accounting for Stock-Based Compensation
 
We account for our stock options and warrants using the fair value method promulgated by Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services. Therefore, our results include non-cash compensation expense as a result of the issuance of stock options and warrants and we expect to record additional non-cash compensation expense in the future.
 
 
22

 
 
 ITEM 4. CONTROLS AND PROCEDURES.
 
Disclosure Controls and Procedures
 
We evaluated the design and operation of our disclosure controls and procedures to determine whether they are effective in ensuring that we disclose required information in a timely manner and in accordance with the Securities Exchange Act of 1934 (the "Exchange Act") and the rules and regulations promulgated by the SEC.  The executive who serves as our President and Chief Financial Officer has participated in such evaluation.  Management concluded, based on such review, that our disclosure controls and procedures, as defined by Exchange Act Rules 13a-15(e) and 15d-15(e), were not effective as of the end of the period covered by this Quarterly Report on Form 10-Q.  The ineffectiveness of these disclosure controls is due to the matters described below in "Internal Control over Financial Reporting."
 
Limitations on the Effectiveness of Controls
 
We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.  Our disclosure controls and procedures are designed to provide a reasonable assurance of achieving their objectives and our President and Chief Financial Officer has concluded that such controls and procedures are not effective at the "reasonable assurance" level.  The ineffectiveness of these disclosure controls is due to the matters described below in "Internal Control over Financial Reporting."
 
Internal Control over Financial Reporting
 
The Company's independent registered public accounting firm has reported certain matters involving internal controls that this firm considered to be reportable conditions and a material weakness, under standards established by Public Company Accounting Oversight Board.  The reportable conditions and material weakness relate to a limited segregation of duties at the Company.  Segregation of duties within our company is limited due to the small number of employees that are assigned to positions that involve the processing of financial information.  Specifically, certain key financial accounting and reporting personnel had an expansive scope of duties that allowed for the creation, review, approval and processing of financial data without independent review and authorization for preparation of consolidation schedules and resulting financial statements and related disclosures. We did not maintain a sufficient depth of personnel with an appropriate level of accounting knowledge, experience and training in the selection and application of Generally Accepted Accounting Principles commensurate with financial reporting requirements.  Accordingly, we place undue reliance on the finance team at corporate headquarters, specifically the executive who is our President and Chief Financial Officer along with outside accounting consulting.  Accordingly, management has determined that this control deficiency constitutes a material weakness.  This material weakness could result in material misstatements of significant accounts and disclosures that would result in a material misstatement to our interim or annual consolidated financial statements that would not be prevented or detected.  In addition, due to limited staffing, the Company is not always able to detect minor errors or omissions in reporting.
 
Going forward, management anticipates that additional staff will be necessary to mitigate these weaknesses, as well as to implement other planned improvements.  Additional staff will enable us to document and apply transactional and periodic controls procedures, permit a better review and approval process and improve quality of financial reporting.  However, the potential addition of new staff is contingent on obtaining additional financing, and there is no assurance that the Company will be able to do so.
 
Management believes that its unaudited condensed financial statements for the three and nine months ended September 30, 2011 and 2010 fairly presented, in all material respects, its financial condition and results of operations.  During the three months ended September 30, 2011, there were no changes to our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 
23

 

PART II
 
ITEM 1. LEGAL PROCEEDINGS.
 
We are not a party to any pending legal proceeding, nor is our property the subject of a pending legal proceeding, that is not in the ordinary course of business or otherwise material to the financial condition of our business. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.
 
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
 
During the nine months ended September 30, 2011, we issued 550,838 shares of common stock to consultants for services rendered in the amount of $569,558- per Note 5 out of which 419,838 common stock were issued for value $458,760 relates to accruals. In connection with the issuance of such shares, we relied on the exemption from registration provided by Section 4(2) of the Securities Act of 1933, as amended.
 
ITEM 6. EXHIBITS.
 
Exhibit
Number
 
Description of Exhibit
     
31.1
 
Certifications required by Rule 13a-14, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1
 
Certification of Chief Executive Officer and Principal Accounting Officer pursuant to 18 U.S.C.§ 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS
 
XBRL Instance Document
     
101.SCH
 
XBRL Taxonomy Extension Schema Document
     
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
 
 
24

 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
IRIS BIOTECHNOLOGIES INC.
 
       
November 16, 2011
By:
/s/ Simon Chin
 
   
Simon Chin
 
   
President, Chief Executive Officer, Chief Financial Officer and Director (Principal Executive Officer, Principal Accounting Officer and Principal Financial Officer)
 
       

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25